Advertisement

Topics

The Angelman Syndrome Foundation Company Profile

07:58 EDT 24th September 2018 | BioPortfolio


News Articles [1120 Associated News Articles listed on BioPortfolio]

UPV/EHU researchers account for the complex symptoms of Angelman syndrome

(University of the Basque Country ) A research group at the Faculty of Science and Technology of the UPV/EHU-University of the Basque Country has managed to reliably identify the changes in the protei...

Ovid’s Angelman Syndrome Therapy Hits Prespecified Endpoint Phase II Trial, Shares Drop Significa...

Ovid Therapeutics is shouting good news from the rooftops regarding its mid-stage Angelman Syndrome study, but investors are not convinced.

Ovid's Angelman syndrome drug shows mixed results in Phase 2

OV101 is trying to be the first treatment for Angelman syndrome, a rare genetic disorder. While it achieved its primary clinical trial goal focused on safety, the efficacy endpoints were mixed, leadin...

Ovid falls on Phase II data for Angelman syndrome candidate

GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment

DOWNERS GROVE, Ill., March 27, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted orphan-drug designation to GeneTx Biotherapeutics LLC’s GTX-101 for the treatment of An...

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

GERMANTOWN, Md., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell te...

Ovid's Angelman syndrome candidate misses behavior, sleep and gait endpoints in Phase II

Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome

-- OV101 achieved primary endpoint of safety and tolerability -- -- Robust and statistically significant improvement (p=0.0006) in the first prespecified efficacy endpoint (CGI-I) observed at 12 we...

Drugs and Medications [450 Associated Drugs and Medications listed on BioPortfolio]

Esika [Ventura Corporation (San Juan, P.R)]

ēsika 3-in-1 Pro Make Up Foundation SPF 20

Sheer cover mineral foundation [Guthy-Renker LLC]

Sheer Cover Mineral Foundation SPF-15

Cle de peau beaute silky foundation i [SHISEIDO CO., LTD.]

CPB Silky Cream Foundation I

Cle de peau beaute foundation i [SHISEIDO CO., LTD.]

cle de peau BEAUTE Cream Foundation I

Shiseido perfect refining foundation [SHISEIDO AMERICA INC.]

SHISEIDO Perfect Refining Foundation

PubMed Articles [2600 Associated PubMed Articles listed on BioPortfolio]

Adrenal Insufficiency, Sex Reversal, and Angelman Syndrome due to Uniparental Disomy Unmasking a Mutation in CYP11A1.

Cholesterol side-chain cleavage enzyme (P450scc) deficiency is a rare genetic disorder causing primary adrenal insufficiency with or without a 46,XY disorder of sexual development (DSD). Herein, we re...

Abnormal coherence and sleep composition in children with Angelman syndrome: a retrospective EEG study.

Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, speech and motor impairments, epilepsy, abnormal sleep, and phenotypic overlap with autism. Individual...

Quantitative proteomics reveals neuronal ubiquitination of Rngo/Ddi1 and several proteasomal subunits by Ube3a, accounting for the complexity of Angelman syndrome.

Angelman syndrome is a complex neurodevelopmental disorder caused by the lack of function in the brain of a single gene, UBE3A. The E3 ligase coded by this gene is known to build K48-linked ubiquitin ...

Detection of a case of Angelman syndrome caused by an imprinting error in 949 pregnancies analyzed for AS following IVF.

Diazepam for outpatient treatment of nonconvulsive status epilepticus in pediatric patients with Angelman syndrome.

Nonconvulsive status epilepticus (NCSE) is present in multiple pediatric neurogenetic syndromes with epileptic encephalopathies. While intravenous (IV) medications are used inpatient for treatment of ...

Clinical Trials [4148 Associated Clinical Trials listed on BioPortfolio]

Study on the Brain Network of Angelman Syndrome

The aims of study on Angelman syndrome: (1)establish the Angelman syndrome database (2)to study the brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data

Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

This study is designed to determine the highest dose of levodopa/carbidopa that can be tolerated without any serious side effects by children with Angelman syndrome. It has been hypothesi...

Characterization of Angelman Syndrome

Angelman Syndrome (AS) is a developmental disorder that is caused by a deficiency of a maternally transmitted gene. It is inherited at birth, and affects movement, speech, and social demea...

Angelman Syndrome Italian Registry

The Italian Angelman Registry is a national registry for patients with Angelman Syndrome. No experimental intervention is involved in participation. The data provided are stored in the reg...

Dietary Supplements for the Treatment of Angelman Syndrome

Angelman syndrome (AS) is a complex genetic disorder that affects the nervous system. The purpose of this study is to determine the effectiveness of certain dietary supplements in treating...

Companies [1498 Associated Companies listed on BioPortfolio]

Angelman Syndrome Foundation

Since 1996, the Angelman Syndrome Foundation has funded 59 research grants totaling more than $3.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($3.3 million) beginn...

Foundation for Angelman Syndrome Therapeutics (FAST)

Angelman Syndrome (AS) was first described by Dr. Harry Angelman in 1965. Common symptoms include developmental delay and intellectual disabilities, happy demeanor, movement and balance disorder, seve...

The Angelman Syndrome Foundation

Sjogren's Syndrome Foundation

Founded in 1983, the Sjogren's Syndrome Foundation (SSF) provides patients with practical information and coping strategies that minimize the effects of Sjogren's syndrome. In addition, the Foundation...

Global Down Syndrome Foundation

The Global Down Syndrome Foundation is a public non-profit 501(c)(3) dedicated to significantly improving the lives of people with Down syndrome through research, medical care, ed...

More Information about "The Angelman Syndrome Foundation" on BioPortfolio

We have published hundreds of The Angelman Syndrome Foundation news stories on BioPortfolio along with dozens of The Angelman Syndrome Foundation Clinical Trials and PubMed Articles about The Angelman Syndrome Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of The Angelman Syndrome Foundation Companies in our database. You can also find out about relevant The Angelman Syndrome Foundation Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record